Pep63 was identified from an array assay to find peptides able to block the EphB2 - Abeta-derived diffusible ligands (ADDL) interaction. ADDLs are soluble amyloid-beta (Abeta) oligomers which constitute a large part of senile plaques and are an important pathogenic factor in Alzheimers disease (AD). Abeta oligomers bind to the fibronectin (FN) type III repeat domain of EphB2 to trigger EphB2 degradation, impairing the normal functioning of NMDA receptors and resulting in cognitive deficits, consequently blocking the interaction of EphB2 and ADDLs is a potential strategy for early treatment of AD. In cultured hippocampal neurons, Pep63 prevents ADDL induced depletion of EphB2- and GluN2B-containing NMDA receptors and rescues the induced impaired synaptic plasticity. In vivo, Pep63 improves memory deficits in APP/PS1 transgenic mice.
Molekulargewicht:
1145.67
Reinheit:
>95% by hplc
Formulierung:
Freeze dried solid
Sequenz:
VFQVRARTVA
Formel:
C51H87N17O13
Target-Kategorie:
Protein-protein interactions
Anwendungsbeschreibung:
ProductType: Peptides
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
